Increased plasma/serum levels of prolactin in systemic lupus erythematosus: a systematic review and meta-analysis

References

• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533.
   PubMed Web of Science ®Google Scholar
• Yang J, Chu Y, Yang X, et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum. 2009;60:1472–1483.
   PubMed Web of Science ®Google Scholar
• Nitzan O, Elias M, Saliba WR. Systemic lupus erythematosus and inflammatory bowel disease. Eur J Intern Med. 2006;17:313–318.
   PubMed Web of Science ®Google Scholar
• Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev. 2012;11:A465–70.
   PubMed Web of Science ®Google Scholar
• Petri M. Sex hormones and systemic lupus erythematosus. Lupus. 2008;17:412–415.
   PubMed Web of Science ®Google Scholar
• Jacobi A, Rohde W, Ventz M, et al. Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus. 2001;10:554–561.
   PubMed Web of Science ®Google Scholar
• Ben-Jonathan N, Mershon JL, Allen DL, et al. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17:639–669.
   PubMed Web of Science ®Google Scholar
• Walker SE, Allen SH, Hoffman RW, et al. Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus. 1995;4:3–9.
   PubMed Web of Science ®Google Scholar
• Costanza M, Binart N, Steinman L, et al. Prolactin: a versatile regulator of inflammation and autoimmune pathology. Autoimmun Rev. 2015;14:223–230.
   PubMed Web of Science ®Google Scholar
• Matera L, Mori M, Galetto A. Effect of prolactin on the antigen presenting function of monocyte-derived dendritic cells. Lupus. 2001;10:728–734.
   PubMed Web of Science ®Google Scholar
• Jara LJ, Benitez G, Medina G. Prolactin, dendritic cells, and systemic lupus erythematosus. Autoimmun Rev. 2008;7:251–255.
   PubMed Web of Science ®Google Scholar
• Walker SE, Allen SH, McMurray RW. Prolactin and autoimmune disease. Trends Endocrinol Metab. 1993;4:147–151.
   PubMed Web of Science ®Google Scholar
• Orbach H, Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun Rev. 2007;6:537–542.
   PubMed Web of Science ®Google Scholar
• Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Bio-Medica: Atenei Parmensis. 2007;78(Suppl 1):255–261.
   PubMedGoogle Scholar
• Peeva E, Michael D, Cleary J, et al. Prolactin modulates the naive B cell repertoire. J Clin Invest. 2003;111:275–283.
   PubMed Web of Science ®Google Scholar
• Peeva E, Venkatesh J, Michael D, et al. Prolactin as a modulator of B cell function: implications for SLE. Biomed Pharmacother. 2004;58:310–319.
   PubMed Web of Science ®Google Scholar
• Lavalle C, Loyo E, Paniagua R, et al. Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol. 1987;14:268–272.
   PubMed Web of Science ®Google Scholar
• Folomeev M, Prokaeva T, Nassonova V, et al. Prolactin levels in men with SLE and RA. J Rheumatol. 1990;17:1569–1570.
   PubMed Web of Science ®Google Scholar
• Jara-Quezada L, Graef A, Lavalle C. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus. J Rheumatol. 1991;18:349–353.
   PubMed Web of Science ®Google Scholar
• Ugarte-Gil MF, Gamboa-Cardenas RV, Zevallos F, et al. High prolactin levels are independently associated with damage accrual in systemic lupus erythematosus patients. Lupus. 2014;23:969–974.
   PubMed Web of Science ®Google Scholar
• Jara LJ, Lavalle C, Espinoza LR. Does prolactin have a role in the pathogenesis of systemic lupus erythematosus?. J Rheumatol. 1992;19:1333–1336.
   PubMed Web of Science ®Google Scholar
• Jimena P, Aguirre MA, Lopez-Curbelo A, et al. Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus. 1998;7:383–386.
   PubMed Web of Science ®Google Scholar
• Buskila D, Lorber M, Neumann L, et al. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus. J Rheumatol. 1996;23:629–632.
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Lee KW, et al. Hyperprolactinemia in males with systemic lupus erythematosus. J Rheumatol. 1998;25:2357–2363.
   PubMed Web of Science ®Google Scholar
• Rovensky J, Jurankova E, Rauova L, et al. Relationship between endocrine, immune, and clinical variables in patients with systemic lupus erythematosus. J Rheumatol. 1997;24:2330–2334.
   PubMed Web of Science ®Google Scholar
• Nakken B, Szodoray P. Accelerated atherosclerosis in rheumatoid arthritis: rationale for mannose-binding lectins?. J Rheumatol. 2010;37:482–484. Epub 2010/03/04.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–1558.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634.
   PubMed Web of Science ®Google Scholar
• Yang J, Li Q, Yang X, et al. Increased serum level of prolactin is related to autoantibody production in systemic lupus erythematosus. Lupus. 2015; 25:513–519.
   Google Scholar
• Handono K. The correlation between the molecular heterogeneity of prolactin and autoantibody and complement levels in patients with systemic lupus erythematosus. Arch Rheumatol. 2014;29:35–41.
   Web of Science ®Google Scholar
• Haghighi A, Lahmi F. Hyperprolactinemia in patients with systemic lupus erythematosus: correlation with disease activity. Asia Pacific League of Associations for Rheumatology. 2006;9:227–231.
   Google Scholar
• Vera-Lastra O, Mendez C, Jara LJ, et al. Correlation of prolactin serum concentrations with clinical activity and remission in patients with systemic lupus erythematosus. Effect of conventional treatment. J Rheumatol. 2003;30:2140–2146.
   PubMed Web of Science ®Google Scholar
• Cruz J, Avina-Zubieta A, Martinez De La Escalera G, et al. Molecular heterogeneity of prolactin in the plasma of patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:1331–1335.
   PubMed Web of Science ®Google Scholar
• Pacilio M, Migliaresi S, Meli R, et al. Elevated bioactive prolactin levels in systemic lupus erythematosus–association with disease activity. J Rheumatol. 2001;28:2216–2221.
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS. Profile of sex hormones in male patients with systemic lupus erythematosus. Lupus. 2000;9:252–257.
   PubMed Web of Science ®Google Scholar
• Chang DM, Chang CC, Kuo SY, et al. Hormonal profiles and immunological studies of male lupus in Taiwan. Clin Rheumatol. 1999;18:158–162.
   PubMed Web of Science ®Google Scholar
• Ferreira C, Paes M, Gouveia A, et al. Plasma homovanillic acid and prolactin in systemic lupus erythematosus. Lupus. 1998;7:392–397.
   PubMed Web of Science ®Google Scholar
• Gutiérrez MA, Garcia ME, Rodriguez JA, et al. Hypothalamic-pituitary-adrenal axis function and prolactin secretion in systemic lupus erythematosus. Lupus. 1998;7:404–408.
   PubMed Web of Science ®Google Scholar
• Miranda JM, Prieto RE, Paniagua R, et al. Clinical significance of serum and urine prolactin levels in lupus glomerulonephritis. Lupus. 1998;7:387–391.
   PubMed Web of Science ®Google Scholar
• Cesario TC, Yousefi S, Carandang G, et al. Enhanced yields of gamma interferon in prolactin treated human peripheral blood mononuclear cells. Proc Soc Exp Biol Med. 1994;205:89–95.
   PubMed Web of Science ®Google Scholar
• Gutierrez MA, Molina JF, Jara LJ, et al. Prolactin and systemic lupus erythematosus: prolactin secretion by SLE lymphocytes and proliferative (autocrine) activity. Lupus. 1995;4:348–352.
   PubMed Web of Science ®Google Scholar
• Stevens A, Ray DW, Worthington J, et al. Polymorphisms of the human prolactin gene–implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus. 2001;10:676–683.
   PubMed Web of Science ®Google Scholar
• McMurray RW, Weidensaul D, Allen SH, et al. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Rheumatol. 1995;22:2084–2091.
   PubMed Web of Science ®Google Scholar
• Walker SE, McMurray RW, Houri JM, et al. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus. Ann N Y Acad Sci. 1998;840:762–772.
   PubMed Web of Science ®Google Scholar